News & Media

A biotech stock at an unwarranted discount

Arix Bioscience narrows annual loss but net asset value decreases

Disc Medicine raises $62.5M for hematology programs

With a year full of readouts ahead, Disc Medicine secures cash from Bain Capital

Bargain Shares 2023

New Approaches for Cancer Therapies: Targeting the DNA Damage Response

Ensoma Announces Financing and Acquisition

Ensoma Acquiring Twelve Bio

On in vivo cell therapy quest, Takeda-backed Ensoma buys a CRISPR upstart and bags $85M

Cancer drug biotech Enliven shifts to reverse to move forward as a public company

Oct. 14 Quick Takes

#AAO22: On the heels of PhIII launch, Aura details second administration route of its ocular oncology drug

Artios Pharma trials new breast cancer treatment

Arix Bioscience NAV falls; portfolio firm Disc to merge with Gemini

A Ben Graham recovery play

Disc Medicine goes public in reverse merger with struggling Gemini Therapeutics

Disc inks Gemini merger, secures cash from starry VC syndicate to advance ex-AbbVie, Roche drugs

The life-sciences industry is a jewel in Britain’s economy

The Killer 50 Profiles

Bargain Shares: A Ben Graham contrarian value play

Sorriso Pharmaceuticals is creating the first orally-delivered anti-inflammatory drug for patients with IBD

New ovarian cancer study to probe causes of PARP inhibitor resistance

FDA Grants Fast Track Designation to HPN217 for R/R Multiple Myeloma

Sorriso Pharmaceuticals Raises $31M in Series A Funding

NEA Co-Leads $31 Million Series A in Sorriso Pharmaceuticals

Biotech vets jump on board a startup, raise cash and take aim at the clinic with anti-inflammatory drugs

Depixus raises €30.6m in Series A financing

Depixus raises €30.6m in Series A financing

Nucleic Acid Analysis Startup Depixus Raises €30.6M in Series A Financing

Bargain shares: On the M&A beat

Intracellular targets, eye cancer therapy and light-activated skincare: Here's the latest on biotech IPOs

Bargain shares: A heavily oversold biotech value recovery play

Investors Hand Disc Medicine $90 Million To Control Hematological Diseases

Roche schizophrenia drug that failed PhIII gets a new life in rare disorder as OrbiMed leads $90M for startup

Disc Medicine nabs $90M for blood disease pipeline, new Roche asset

Artios’ $153M series C to expand DDR platform beyond synthetic lethality

Novartis partner Artios bags megaround to drive clinical work on DNA damage repair factors

Artios raises $153M to fund DNA damage repair clinical trials

In Vivo's 2021 Rising Leaders: Recognizing Talent Across The Life Sciences

Inside Track: Amplyx's Ciara Kennedy is on the boil after fungi-fighting Pfizer buyout

Amplyx laid out a promising path to a pivotal antifungal drug trial, and now Pfizer is scooping it all up in a buyout

Pfizer buys Amplyx to grow infectious disease pipeline

Artios, Novartis form cancer therapies collaboration

Novartis taps Artios for targets to enhance radioligand drugs

Five Investment Company Bargains

Oncology startup to double size with $152M

Clean up with two deep value plays

New Company Twelve Bio Aims To Improve On CRISPR Gene-Editing Tech

Arix Bioscience reports FY20NAV up 62%

Arix Bioscience sees sharp uplift in net asset value in 2020

Arix Bioscience Shares Rally 5.4% as Net Asset Value Surges on VelosBio Sale to Merck

Arix Bioscience sees value rocket 62% as UK biotech scene booms

The Fight Against Fungi

Bargain shares for 2021

LSX London 2021 Biotech - Accelerating Innovation Through Early-Stage Investment

Biden administration – What can the healthcare industry expect?

Around the World in Venture Capital

David Stevenson: This is my portfolio for 2021

Exploit Arix Bioscience’s huge margin of safety

Arix Bioscience portfolio company Atox Bio announces FDA acceptance of its NDA for ‘flesh-eating’ disorder treatment

Why Tech trend is worth following beyond 2020

Arix Bioscience shares rise on collaboration deal with Merck KGaA

Arix Bioscience portfolio company Artios signs cancer collaboration deal with Merck KGaA worth up to $7bn

Latest takeovers focus on two specific groups of stocks

Deal-Making During A Pandemic And 2021 Expectations